Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib

Cellular Physiology and Biochemistry

Volumn 34, Issue 3, 2014, Pages 865-872

  Yun, Miyong ^a   Kim, Eun Ok ^a,b   Lee, Duckgue ^a   Kim, Ji Hyun ^a   Kim, Jaekwang ^a   Lee, Hyemin ^a   Lee, Jihyun ^a   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

AKT; Bad; Bcl 2; EGFR; H1975; HCC827; Melatonin

Indexed keywords

CASPASE 3; CYCLIN A; CYCLIN D; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MELATONIN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P21; SURVIVIN; SYNAPTOPHYSIN; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL DEATH; CELL POPULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MELATONIN; MUTATION; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84927137210     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000366305     Document Type: Article

References (34)

1. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G: American society of clinical oncology provisional clinical opinion: Epidermal growth factor receptor (egfr) mutation testing for patients with advanced non-small-cell lung cancer considering firstline egfr tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-2127.
2. Stella GM, Scabini R, Inghilleri S, Cemmi F, Corso S, Pozzi E, Morbini P, Valentini A, Dore R, Ferrari S, Luisetti M, Zorzetto M: Egfr and kras mutational profiling in fresh non-small cell lung cancer (nsclc) cells. J Cancer Res Clin Oncol 2013;139:1327-1335.
3. Kerr KM: Clinical relevance of the new iaslc/ers/ats adenocarcinoma classification. J Clin Pathol 2013;66:832-838.
4. Shim HS, Lee da H, Park EJ, Kim SH: Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the international association for the study of lung cancer/ american thoracic society/european respiratory society lung adenocarcinoma classification. Arch Pathol Lab Med 2011;135:1329-1334.
5. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R: Fda drug approval summary: Erlotinib (tarceva) tablets. Oncologist 2005;10:461-466.
6. Sato C, Nishizawa K, Nakamura H, Komagoe Y, Shimada K, Ueda R, Suzuki S: Monoclonal antibody against microtubule associated protein-1 produces immunofluorescent spots in the nucleus and centrosome of cultured mammalian cells. Cell Struct Funct 1983;8:245-254.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
9. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: Egfr mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
10. Gow CH, Shih JY, Chang YL, Yu CJ: Acquired gefitinib-resistant mutation of egfr in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation l858r. PLoS Med 2005;2:e269.
11. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: Egfr mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792.
12. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the egfr kinase domain. PLoS Med 2005;2:e73.
13. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, Suehisa H, Ouchida M, Aoe K, Aoe M, Kiura K, Shimizu N, Date H: Presence of epidermal growth factor receptor gene t790m mutation as a minor clone in nonsmall cell lung cancer. Cancer Res 2006;66:7854-7858.
14. Macchi MM, Bruce JN: Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 2004;25:177-195.
15. Blask DE, Sauer LA, Dauchy RT: Melatonin as a chronobiotic/anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002;2:113-132.
16. Proietti S, Cucina A, Reiter RJ, Bizzarri M: Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol Life Sci 2012;70:2139-2157.
17. Rodriguez-Garcia A, Mayo JC, Hevia D, Quiros-Gonzalez I, Navarro M, Sainz RM: Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis. J Pineal Res 2012;54:33-45.
18. Suwanjang W, Phansuwan-Pujito P, Govitrapong P, Chetsawang B: The protective effect of melatonin on methamphetamine-induced calpain-dependent death pathway in human neuroblastoma sh-sy5y cultured cells. J Pineal Res 2010;48:94-101.
19. Zhang S, Zuo L, Gui S, Zhou Q, Wei W, Wang Y: Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin. Mol Biol Rep 2012;39:2843-2849.
20. Haus E, Dumitriu L, Nicolau GY, Bologa S, Sackett-Lundeen L: Circadian rhythms of basic fibroblast growth factor (bfgf), epidermal growth factor (egf), insulin-like growth factor-1 (igf-1), insulin-like growth factor binding protein-3 (igfbp-3), cortisol, and melatonin in women with breast cancer. Chronobiol Int 2001;18:709-727.
21. Luchetti F, Betti M, Canonico B, Arcangeletti M, Ferri P, Galli F, Papa S: Erk mapk activation mediates the antiapoptotic signaling of melatonin in uvb-stressed u937 cells. Free Radic Biol Med 2009;46:339-351.
22. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S: Somatic egfr mutations and efficacy of tyrosine kinase inhibitors in nsclc. Nat Rev Clin Oncol 2009;6:352-366.
23. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
24. Rosell R, Taron M, Reguart N, Isla D, Moran T: Epidermal growth factor receptor activation: How exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 2006;12:7222-7231.
25. Tidow N, Boecker A, Schmidt H, Agelopoulos K, Boecker W, Buerger H, Brandt B: Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development. Cancer Res 2003;63:1172-1178.
26. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in taiwan. Clin Cancer Res 2004;10:8195-8203.
27. Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, Yan Z, Li X, Corson JM, Meng F, Zhou H, Sheng Q, Fletcher JA, Ou WB: Multipoint targeting of the pi3k/mtor pathway in mesothelioma. Br J Cancer 2014;110:2479-2488.
28. Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol 2007;35:495-516.
29. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK: Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. Cell Prolif 2012;45:487-498.
30. Czabotar PE, Lessene G, Strasser A, Adams JM: Control of apoptosis by the bcl-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15:49-63.
31. Kroemer G, Blomgren K: Mitochondrial cell death control in familial parkinson disease. PLoS Biol 2007;5:e206.
32. Mita AC, Mita MM, Nawrocki ST, Giles FJ: Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14:5000-5005.
33. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241.
34. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME: Regulation of neuronal survival by the serine-threonine protein kinase akt. Science 1997;275:661-665.